-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly's retatrutide cuts knee osteoarthritis pain by up to 75.8% in Phase 3 trial

PUBT·11/05/2026 11:52:41
Eli Lilly's retatrutide cuts knee osteoarthritis pain by up to 75.8% in Phase 3 trial
  • Eli Lilly will present retatrutide and Taltz-Zepbound trial results at ACR Convergence, Nov. 6-11, 2026, in Orlando.
  • Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed investigational retatrutide reduced knee osteoarthritis pain and weight; some participants finished treatment without knee pain.
  • In Phase 3b TOGETHER-PsA, Taltz with Zepbound improved disease control versus Taltz alone at one year in adults with psoriatic arthritis and obesity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611050645PR_NEWS_USPR_____DE89255) on November 05, 2026, and is solely responsible for the information contained therein.